Denmark's Bavarian Nordic said on Monday the U.S. Food and Drug Administration has approved a freeze-dried formulation of its ...

Yesterday the US Food and Drug Administration (FDA) approved a freeze-dried formulation of Bavarian Nordic's mpox vaccine, ...

This recent safety and effectiveness data regarding mpox vaccination with Jynneos is important and timely given the ongoing ...

By Medha Singh and Sukriti Gupta (Reuters) -European shares rebounded on Tuesday after touching a two-month low in the ...

European shares rose on Tuesday following a pullback in the previous session, although the mood remained cautious ahead of ...

Several Democratic-led states have taken legal action against the Trump administration over its decision to retract $11 ...

Europe’s pharmaceutical sector is bracing for the potential impact of U.S. tariffs as hopes of an industry-wide exemption by President Donald Trump fade.

The latest health updates include the FDA's approval of a new freeze-dried mpox vaccine, and a judge's dismissal of a $10 ...

Audited results confirm full-year revenue of DKK 5,716 million and EBITDA of DKK 1,603 million. Two new early-stage pipeline programs, Lyme disease and Epstein-Barr Virus (EBV), introduced.

The formulation allows for greater stockpiling, with Bavarian Nordic already working with the US government to add to vaccine ...

The Company has been contracted by the U.S Biomedical Advanced Research and Development Authority (BARDA) to develop and supply a freeze-dried version of JYNNEOS for stockpiling. Manufacturing under ...